Optimizing Gastroenterology Surescripts Integration for Specialty Drug PAs

Klivira's **gastroenterology Surescripts integration** empowers GI practices to automate prior authorizations for high-cost specialty medications, reducing manual burden and accelerating patient access to critical therapies.

For revenue cycle directors and prior authorization coordinators in gastroenterology, managing the volume and complexity of specialty drug PAs is a significant operational challenge. Delays in securing approvals for biologics and other advanced therapies can impact patient care pathways and clinic efficiency. Klivira provides a robust solution designed to streamline these intricate workflows.

The Critical Role of Surescripts in GI Pharmacy Benefit PAs

In gastroenterology, a substantial portion of prior authorization burden stems from specialty drugs managed under the pharmacy benefit, particularly for chronic conditions like Inflammatory Bowel Disease (IBD) and Hepatitis C. Surescripts ePA provides the standardized electronic channel to submit these requests, facilitating real-time eligibility checks and prior authorization submissions directly from the EMR for agents such as Humira, Stelara, and Epclusa.

Key GI Medications Requiring Surescripts ePA

IBD Biologics (e.g., adalimumab/Humira, ustekinumab/Stelara, risankizumab/Skyrizi, vedolizumab/Entyvio, tofacitinib/Xeljanz, upadacitinib/Rinvoq, ozanimod/Zeposia, etrasimod/Velsipity) — often self-administered via pharmacy benefit.
Hepatitis C Direct-Acting Antivirals (e.g., sofosbuvir-velpatasvir/Epclusa, glecaprevir-pibrentasvir/Mavyret) — requiring genotype and fibrosis stage documentation.
Specialty drugs for functional GI disorders (e.g., eluxadoline/Viberzi, prucalopride/Motegrity, linaclotide/Linzess, plecanatide/Trulance) — requiring diagnosis criteria and prior conservative-therapy trials.

Streamlining EMR and Payer Touchpoints for GI PAs

Klivira's integration with leading EMRs through SMART on FHIR enables GI practices to initiate Surescripts ePA requests directly from the patient chart. This eliminates duplicate data entry and ensures that necessary clinical documentation, such as Mayo scores for UC or CDAI for Crohn's, along with TB and hepatitis screening results, are automatically populated and transmitted via NCPDP SCRIPT standards for pharmacy benefit PAs.

Adhering to Clinical Guidelines and Payer Policies

Effective **gastroenterology Surescripts integration** demands adherence to complex clinical guidelines from bodies like the ACG (American College of Gastroenterology), AGA (American Gastroenterological Association), and AASLD (American Association for the Study of Liver Diseases). Klivira's platform incorporates these guidelines into its logic, ensuring that submissions meet payer-specific medical necessity criteria, including step therapy requirements for IBD biologics or fibrosis staging for Hep C DAAs, minimizing common denial reasons such as biosimilar substitution issues or missing severity scores.

Klivira's Differentiated Approach to GI Surescripts Workflows

Klivira specifically addresses the unique challenges of GI prior authorization, including the chronic re-authorization burden for IBD biologics and the distinction between treatment-naive and treatment-experienced patient pathways for both IBD and Hep C. Our system automates periodic re-authorization notifications and guides users through documentation requirements, ensuring compliance with payer policies and reducing manual follow-ups for critical pharmacy benefit medications.

Frequently asked questions

How does Klivira's Surescripts integration handle the medical vs. pharmacy benefit split for GI biologics?

Klivira's platform intelligently routes prior authorization requests based on the specific drug and its administration method. For self-administered IBD biologics, which often fall under the pharmacy benefit, our Surescripts integration facilitates electronic submissions via NCPDP SCRIPT. For provider-administered infusions under the medical benefit, we leverage other electronic channels, ensuring the correct pathway is always used.

Can Klivira help with step therapy requirements for IBD biologics submitted via Surescripts ePA?

Yes, Klivira's system is pre-configured with ACG and AGA guideline-aware step therapy logic for IBD biologics. When initiating a Surescripts ePA, the platform prompts for documentation of prior conventional therapies or previous biologic trials, helping to ensure compliance with payer policies and reduce denials related to step therapy.

What specific documentation does Klivira's Surescripts integration help gather for Hepatitis C DAA PAs?

For Hepatitis C DAA prior authorizations submitted via Surescripts, Klivira's integration assists in gathering critical documentation such as genotype, fibrosis stage (e.g., FibroSure, transient elastography), prior-treatment history, and relevant coinfection status. This ensures comprehensive submissions that meet payer medical necessity criteria.

Does Klivira automate re-authorizations for chronic GI conditions like IBD?

Yes, Klivira's platform includes robust features for managing periodic re-authorizations for chronic GI conditions. For IBD biologics requiring ongoing approval, the system tracks authorization expiry dates and proactively initiates the re-authorization workflow, prompting for updated disease activity scores and response documentation to maintain continuous patient access.

How does Klivira's Surescripts integration improve turnaround times for GI PAs?

By automating data extraction from the EMR, performing real-time eligibility checks, and enabling electronic submission via the Surescripts network, Klivira significantly reduces the manual effort and potential for errors in GI prior authorizations. This streamlined process accelerates the submission-to-approval cycle, leading to faster turnaround times for critical specialty drugs.